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Gastric hyperplastic polyps (GHps) have a potential risk of neoplastic transformation, but the 
responsible mechanisms have not yet been established. We conducted a study involving 55 patients 
(33 female) who had undergone endoscopic or surgical resection of GHPs. We compared 16 patients 
who had GHPs showing neoplastic transformation with 39 patients who had non-neoplastic GHPs. We 
analyzed differences in serology, gastroscopic manifestations and pathology between the two groups 
in order to establish risk factors that may be associated with neoplastic transformation. The mean age 
of the cohort was 61.73 ± 9.024 years. The prevalence of positive serum gastric parietal cell antibody 
(PCA) was 61.8%. 30 of the GHPs with neoplastic formation had a “strawberry-like” appearance with 
erosions of polyps (P = 0.000). A history of anaemia was a risk factor for GHPs which demonstrated 
neoplastic transformation (odds ratio [OR], 3.729; 95% confidence interval [CI], 1.099–12.649; 
P = 0.035). Although the differences were not significant, our data showed higher prevalences of 
positive serum pcA (P = 0.057), hypergastrinemia (P = 0.062) and female gender (P = 0.146) in the GHP 
patients who had neoplastic transformation. Multiple polyps in the corpus (P = 0.024) occurred more 
frequently in serum PcA positive patients. Hypergastrinemia occurred more frequently in Helicobacter 
pylori negative patients and of these 20/22 patients had a positive PCA (P = 0.007). GHPs are associated 
with autoimmune metaplastic atrophic gastritis (AMAG). AMAG is probably one of the risk factors for 
GHps to undergo neoplastic transformation.
Gastric hyperplastic polyps (GHPs) are one of the most common type of polyp encountered in the stomach1. 
They constitute 30–93% of all benign epithelial gastric polyps2–4 and occur in patients of either gender and are 
more common with increasing age (65 to 70 years on average)5. GHPs are usually asymptomatic and are often 
diagnosed incidentally during routine esophagogastroduodenoscopy (EGD). However they may cause anaemia. 
GHPs can be sessile or pedunculated and can occur as single or multiple polyps in the antrum or corpus of 
the stomach. The diameter of GHPs is usually less than 1 cm, however 10% measure greater than 2 cm6. GHPs 
commonly arise within a background of chronic gastritis, including Helicobacter pylori-related gastritis (type B 
gastritis), as well as autoimmune metaplastic atrophic gastritis (AMAG, type A gastritis)7. Up to 70–80% of GHPs 
have been found to regress after eradication of Helicobacter pylori and these polyps do not need to be removed 
endoscopically8,9.
GHPs have a potential risk of neoplastic transformation, so they have been classified as potentially precancer-
ous lesions. With the recent more widespread use of endoscopic resection of gastric polyps, an increased num-
ber of cases of dysplasia or carcinoma within GHPs has been reported10. The responsible mechanisms however 
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remain unknown. This study aimed to analyze possible risk factors that are associated with the neoplastic trans-
formation of gastric hyperplastic polyps.
Results
Demographics features. During January 2010 and June 2017, there were 6418 cases of gastric polyp diag-
nosed. 1115 of these (17.4%, 1115/6418) were histologically confirmed GHPs. 30 of these GHPs (2.69%, 30/1115) 
were diagnosed as containing dysplasia or adenocarcinoma. The mean age was 61.73 ± 9.024 years old (range 
32–79). Absence of Helicobacter pylori was found in 63.6% (35/55). Within the 16 patients who showed evidence 
of neoplastic transformation there were 12 females and 4 males, the mean age was 63.44 ± 12.27 years (range 
32–79). 9 (56.3%) of the patients who had GHPs with neoplastic transformation and 10 (25.6%) of the patients 
with pure GHPs had a history of anaemia. The patients who had a history of anaemia were more likely to have 
GHPs with evidence of neoplastic transformation (9/16 vs 10/39 in the GHP patients with or without neoplastic 
transformation, χ2 = 4.701, P = 0.030) (Table 1).
The initial indications for performing EGD were: 27 patients screening for early gastric cancer, 15 bloating, 
4 abdominal pain, 7 heartburn or acid reflux and 2 anaemia. However, 20 patients (36.4%) actually had evi-
dence of anaemia when tested. Only 3 patients took PPI, but all of them had normal fasting serum gastrin-17 
concentrations.
Serum tests in GHP patients with or without neoplastic transformation. The positive rate of 
serum anti-gastric parietal cell antibody (PCA) was 61.8% (34/55), 13/16 vs 21/39 in GHP patients with or with-
out neoplastic transformation (χ2 = 3.610, P = 0.057). Only 6 patients (6/55) had positive anti-intrinsic factor 
antibodies. Hypergastrinemia occurred in 27 patients, 11 of whom were GHP patients with neoplastic transfor-
mation (11/16, χ2 = 3.489, P = 0.062). 20 patients had anaemia, 9/16 vs 11/39 in GHPs with or without neoplastic 
transformation (χ2 = 3.856, P = 0.05). There were 33 females in the study, 12/16 vs 21/39 in GHPs with or without 
neoplastic transformation (χ2 = 2.115, P = 0.146). Although, there were no significant differences in terms of 
positive PCA, hypergastrinemia or gender, there appeared to be trends in these parameters in those patients who 
had GHPs with neoplastic transformation (Table 2).
Endoscopic characteristics of GHPs with or without neoplastic transformation. There were 
141 GHPs in total in the 55 patients, including 31 GHPs which had evidence of neoplastic transformation 
(the locations were: fundus 6, corpus 20 and antrum 5) and 110 pure GHPs (located in: fundus 27, corpus 58 
and antrum 25). 30 of the GHPs with neoplastic formation had a “strawberry-like” appearance with erosions 
at the head of polyps, 30/31 vs 67/110 in GHPs with or without neoplastic transformation (χ2 = 14.491, 
P = 0.000)(Table 3). Polyps occurring in the patients who had positive serum PCA were more frequently 
found in the fundus and corpus than the antrum (90/111 vs 17/30 in the fundus and corpus vs antrum, 
χ2 = 7.693, P = 0.006).
The characteristics of GHP patients who had anaemia. 20 (20/55) patients had anaemia, of whom 
16 patients had iron deficiency (16/20 vs 4/35 in patients with or without anaemia, χ2 = 25.861, P = 0.000), 
6 had vitamin B12 deficiency and 3 patients had both iron and vitamin B12 deficiency. Women were four 
times more likely than men to be anaemic (16/20 vs 17/35 in patients with or without anaemia, χ2 = 5.238, 
P = 0.022). 19 patients had a history of anaemia, of whom 17 patients had current anaemia and 16 patients had 
a positive PCA.
The characteristics of GHP patients who had evidence of helicobacter pylori infection. 20 
(20/55) patients had evidence of Helicobacter pylori infection. Interestingly, hypergastrinemia occurred more 
Parameters 
mean ± SD; n (%)
Total 
(n = 55)
GHP patients with neoplastic 
formation (n = 16)
GHP patients without neoplastic 
formation (n = 39) P value
Age (years) 61.73 ± 9.02 63.44 ± 12.27 61.03 ± 7.39 0.373
BMI(Kg/m2) 24.7 ± 4.14 25.88 ± 4.75 24.22 ± 3.82 0.179
Gender 0.146
  Male 22 (40.0) 4 (25.0) 18 (46.2)
  Female 33 (60.0) 12 (75.0) 21 (53.8)
H. pylori infection 0.262
  Yes 20 (36.4) 4 (25.0) 16 (41.0)
  No 35 (63.6) 12 (75.0) 23 (59.0)
History of anaemia 0.030
  Yes 19 (34.5) 9 (56.3) 10 (25.6)
  No 36 (65.5) 7 (43.8) 29 (74.4)
Table 1. Demographics features of GHP patients. The history of anaemia showed significant difference between 
GHP patients with and without neoplastic formation, tested by Chi-square test (P = 0.030). GHP, gastric 
hyperplastic polyp; BMI, body mass index; SD, standard error; H. pylori, Helicobacter pylori.
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frequently in the patients who did not have H. pylori infection (5/20 vs 22/35 in GHPs with or without H. pylori 
infection, χ2 = 7.299, P = 0.007).
Pathological characteristics of GHPs with or without neoplastic transformation. Seven patients 
had adenocarcinoma (6 females, 1 male) of which 5 were well-differentiated and 2 were moderately-differentiated 
cancers. Three female patients had GHPs that contained foci of high grade dysplasia and 6 patients had GHPs 
containing areas of low grade dysplasia (3 females, 3 males). No metastases were found in any patients. However 
only 3 of these patients had been diagnosed with GHPs that showed neoplastic transformation by initial forceps 
biopsy prior to endoscopic resection. 13 out of the 16 GHPs with neoplastic transformation were only diagnosed 
following EMR or ESD, so the severity of disease was underestimated before resection in 81.3% (13/16) of these 
patients.
Evaluation of the background mucosa was undertaken in 14 of the patients who had GHPs with neoplastic 
transformation. 10 of these patients were diagnosed with autoimmune metaplastic atrophic gastritis (AMAG) or 
enterochromaffin-like cell (ECL-cell) hyperplasia (all had positive serum PCA); 3 patients had intestinal meta-
plasia in the corpus (2 had positive serum PCA) and 1 patient had chronic gastritis and positive serum PCA. The 
pathological characteristics of the GHPs which had neoplastic transformation are recorded in Table 4.
Potential risk factors for GHPs with or without neoplastic transformation. Univariate and mul-
tivariate logistic regression analyzes was performed to explore potential associations between risk factors and 
the presence of neoplastic transformation in GHPs. Continuous variables were transformed into grade variables 




GHP patients with neoplastic 
formation (n = 16)
GHP patients without neoplastic 
formation (n = 39) P value
Hypergastrinemia 0.062
  Yes 27 (49.1) 11 (68.8) 16 (41.0)
  No 28 (50.9) 5 (31.3) 23 (59.0)
PCA 0.057
  Positive 34 (61.8) 13 (81.3) 21 (53.8)
  Negative 21 (38.2) 3 (18.8) 18 (46.2)
IF 0.660
  Positive 6 (10.9) 1 (6.3) 5 (12.8)
  Negative 49 (89.1) 15 (93.8) 34 (87.2)
Anaemia 0.050
  Yes 20 (36.4) 9 (56.3) 11 (28.2)
  No 35 (63.6) 7 (43.8) 28 (71.8)
Ferritin 0.629
  Low 18 (32.7) 6 (37.5) 12 (30.8)
  Normal 37 (67.3) 10 (62.5) 27 (69.2)
Hypothyroidism 0.258
  Yes 9 (16.4) 1 (6.3) 8 (20.5)
  No 46 (83.6) 15 (93.8) 31 (79.5)
Table 2. Serum tests results in GHP patients with or without neoplastic transformation. PCA, serum anti-
parietal cell antibody; IF, anti-intrinsic factor antibody.
Parameters n (%)
GHPs with neoplastic 
formation(n = 31)
GHPs without neoplastic 
formation(n = 110) P value







  ≥1 cm 26(83.9) 84(76.4)
  <1 cm 5(16.1) 26(23.6)
Table 3. Endoscopic features of GHPs with or without neoplastic formation. The “Strawberry-like” with 
erosions showed significant difference between GHPs with and without neoplastic formation, tested by Chi-
square test (P < 0.001).
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history of anaemia was significantly associated with GHPs that showed neoplastic transformation (odds ratio 
[OR], 3.729; 95% confidence interval [CI], 1.099–12.649; P = 0.035). The other factors tested were not signif-
icantly associated with GHPs that demonstrated neoplastic transformation (all p values ≥0.05) (Table 5). In 
addition, when history of anaemia, hypergastrinemia, ferritin, PCA and anaemia were added into a multivariate 
logistic regression model, the results still showed that a history of anaemia was significantly associated with GHPs 
that demonstrated neoplastic transformation (OR = 5.603; 95% CI: 1.167–26.899; P = 0.031).
Discussion
GHPs used to be the most common polyps of benign epithelial gastric polyps1. However, the prevalence of GHPs 
has decreased to 14–40% of gastric polyps in recent decades11–13. In our study of 6418 cases of gastric polyp, 
1115 cases (17.4%, 1115/6418) were GHPs. These data are similar to those reported in US14. A Japanese study 
reported that all GHPs were more common in females, but that the sex ratio of GHPs that contained carcinoma 
was 1:115. In our study, female gender was slightly preponderant overall (F:M = 1.5:1), and this was especially in 
the patients who had GHPs with neoplastic transformation (F:M = 3:1). To date, dysplasia or adenocarcinoma has 
been infrequently described in GHPs, and these polyps are therefore generally interpreted as being benign lesions 
which have a malignant potential but also act as markers for the precancerous condition of the gastric mucosa16. 
The reported prevalence of dysplasia in GHPs has varied from 1.9–19%17,18; the frequency of infiltrating adeno-
carcinoma arising in GHPs has been debated but has ranged from 0–13.5%19,20. In our study 2.69% (30/1115) of 
patients who were diagnosed with GHPs showed evidence of dysplasia or adenocarcinoma within these polyps.
In this study we noticed a phenomenon of an unusual environment in which GHP neoplastic transformation 
may occur: namely an association between neoplastic GHPs and the presence of AMAG in the background gas-
tric mucosa. Some GHPs showed evidence of focal neuroendocrine differentiation or ECL-cell hyperplasia in the 
gastric mucosa surrounding the tumor. Whether the presence of AMAG may constitute an additional risk factor 
for neoplastic change within GHPs remains uncertain. Some case reports have described the probable relation-
ship between GHPs and dysplasia or carcinoma21–23. Neuroendocrine differentiation occurs in 39.6% of gastric 
cancer cases and occurs more frequently in poorly differentiated cancers than in well differentiated tumors24.
The approximate annual detection rate of AMAG reported recently by Hejun Zhang et al. in China is about 
0.9%25, which is similar to the incidence in Asians (1.4%) reported by Park et al.26. Patients with AMAG are 
more likely to develop gastric polyps and neoplasms. In Park’s study, 143 of 461 (31%) patients with AMAG had 
gastric lesions: 138 of these were GHPs, 21 were adenomas and 11 were adenocarcinomas. The importance of 
GHPs appears to lie most significantly in their status as a marker for an abnormal background gastric mucosa 








mucosa Pathology of EMR/ESD/Surgery
1 F 69 + − >2 cm M(C) C S Gastritis with IM AMAG/ECL-cell hyperplasia HGD
2 F 77 + − >2 cm M(F + C + A) F + C + A P GHP with HGD AMAG Well-differentiated adenocarcinoma (17 polyps,10/17 polyps with carcinoma)
3 F 59 + − >1 cm M (C + A) C P GHP AMAG/ECL-cell hyperplasia Well-differentiated adenocarcinoma
4 F 66 + − >2 cm M (C + A) C + A P GHP AMAG/ECL-cell hyperplasia
Moderately-differentiated 
adenocarcinoma /HGD (Surgery: lv 
invasion, Ki-67:70%)
5 F 59 + + >1 cm M(C) C P GHP with HGD ECL-cell hyperplasia Well-differentiated adenocarcinoma
6 F 78 + − >1 cm S(F) F P GHP AMAG Well-differentiated adenocarcinoma
7 F 65 + − >1 cm S(A) A P Gastritis with IM AMAG/ECL-cell hyperplasia HGD
8 F 44 − − >1 cm S(Cardia) Cardia S GHP ND LGD





10 F 58 + − >1 cm M(F + C) F P Gastritis AMAG/ECL-cell hyperplasia HGD
11 F 32 − + >1 cm S(C) C P GHP ND LGD
12 F 79 + − >1 cm M(F + C) F + C P GHP with HGD AMAG/ECL-cell hyperplasia
Moderately-differentiated 
adenocarcinoma/HGD





14 M 64 + + <1 cm M (C + A) C S GHP IM LGD
15 M 68 + + >2 cm S(C) C P GHP Chronic gastritis LGD
16 M 60 + − >2 cm M(C) C P Gastritis with IM AMAG/ECL-cell hyperplasia Well-differentiated adenocarcinoma
Table 4. Summary of pathological data on patients with GHPs demonstrating neoplastic transformation. M, 
male; F, female; M, multiple; S, single; F, fundus; C, corpus; A, antrum; P, pedunculated; S, sessile; IM, intestinal 
metaplasia; AMAG, autoimmune metaplastic atrophic gastritis; ECL-cell, enterochromaffin-like cell; HGD, high 
grade dysplasia; LGD, low grade dysplasia; lv, lymphovascular; ND, not done.
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rather than as isolated pre-neoplastic lesions. GHPs arise most commonly in a background of abnormal and often 
atrophic gastric mucosa. In Abraham’s study27, the true rate of a normal or only mildly abnormal gastric mucosal 
background in patients with GHPs was probably lower than 15%. The data demonstrated that 25% GHPs arose 
in the setting of active chronic H. pylori gastritis, 21% arose in association with reactive/chemical gastropathy, 
and 12% arose in autoimmune gastritis. According to Orlowska et al.28, the risk of malignancy developing in the 
gastric mucosa outside the polyp is slightly higher than that within the polyp itself. Markowski et al. also showed 
that the chance of malignant development in the surrounding mucosa was 7.1%, whereas within the polyp itself 
it was 2.1%29. The risk of gastric cancer developing in subjects with severe fundal atrophic gastritis was 5.76 
times greater than in those having little or no fundal atrophic gastritis30. Pathologists diagnosing GHP in patients 
who have not had adequate biopsies of the non-polypoid stomach should therefore reiterate this association and 
recommend that biopsies of the surrounding mucosa be taken to evaluate any underlying gastric abnormalities. 
In addition, as we know, atrophic gastritis and intestinal metaplasia are the major precursor lesions of gastric 
adenocarcinoma. However, a Japanese study suggested that intestinal metaplasia within GHPs was not associ-
ated with carcinogenesis within these polyps. They suggested that GHPs with neoplastic changes develop via a 
hyperplasia-dysplasia-carcinoma sequence rather than an intestinal metaplasia-dysplasia-carcinoma sequence20.
It is well known that GHPs are commonly associated with H. pylori infection, and GHPs regress in the great 
majority of cases following eradication of this infection. In a large cohort study by Nam et al., H. pylori infec-
tion was associated with a 2-fold increased risk of diagnosing GHPs, while successful H. pylori eradication and 
persistent H. pylori negative status resulted in an 11.7- fold increase in the clearance of GHPs compared to con-
trol31. Some patients with H. pylori infection may have hypergastrinemia, but in this study, hypergastrinemia 
occurred more frequently in the patients who did not have H. pylori infection. This is probably because most of 
the H. pylori negative patients (30/55) had positive PCAs and thus an alternative cause of hypochlorhydria and 
hypergastrinemia.
Interestingly, the patients who had positive PCA were more likely to have iron deficiency anaemia than vita-
min B12 deficiency. This is probably because the progression of AMAG to pernicious anaemia (PA) is likely to 
take 20–30 years32, PA with vitamin B12 deficiency occurs in the later stages of AMAG. The incidence of gastric 
hyperplastic polyps in iron-deficient patients was reported to be 1.4%33. In our study, logistic regression analysis 
showed that a history of anaemia was a significant risk factor for GHPs that showed neoplastic transformation. 
This has not been reported in previous studies. 19 patients had a history of anaemia, of whom 17/19 had current 
anaemia and 16/19 had a positive PCA. Whether or not this means that long term anaemia correlates with the 
presence of AMAG remains speculative however.
In conclusion, GHPs are associated with the presence of AMAG, and this may be responsible for neoplastic 
transformation in some cases, and hypergastrinemia may contribute. Our study suggests that a history of anaemia 
is more likely to have GHPs which develop neoplastic transformation. The main limitation of our study was the 
small sample size which has reduced its statistical power to investigate whether or not the coexistence of GHP 
and AMAG (or ECL-cell hyperplasia) confers an increased risk of developing dysplasia and carcinoma. However, 
additional research on this topic is urgently needed.
Methods
The hospital based study was conducted at the Beijing Friendship Hospital, Capital Medical University, China. 
During January 2010 and June 2017. There were 6418 cases of gastric polyp diagnosed. 1115 patients were his-
tologically confirmed GHPs, 701 female patients and 414 male patients. 30 patients who had GHPs that demon-
strated neoplastic transformation including adenocarcinoma, high grade dysplasia and low grade dysplasia were 
diagnosed. 16 of these GHP patients agreed to participate in this study and therefore underwent additional eval-
uations. 60 GHP patients who didn’t show neoplastic transformation were randomly selected from 1085 patients 
Variables 95%CI OR P value
Age (<60 years vs. ≥60years) 0.291–3.595 1.023 0.972
BMI (<24 kg/m2 vs. ≥24 kg/m2) 0.140–1.636 0.478 0.240
Gender (Male vs. Female) 0.107–1.420 0.389 0.153
H. pylori infection (Yes vs. No) 0.131–1.757 0.479 0.267
Hypergastrinemia (Yes vs. No) 0.920–10.871 3.162 0.068
PCA (Postive vs. Negative) 0.912–15.129 3.714 0.067
IF (Postive vs. Negative) 0.049–4.222 0.453 0.487
Anaemia (Yes vs. No) 0.977–10.966 3.273 0.055
Serum iron (Low vs. Normal) 0.683–7.417 2.250 0.183
Vit B12 (Low vs. Normal) 0.377–6.156 1.524 0.554
Ferritin (Low vs. Normal) 0.399–4.570 1.350 0.630
Hypothyroidism (Yes vs. No) 0.030–2.259 0.258 0.221
History of anaemia (Yes vs. No) 1.099–12.649 3.729 0.035
Table 5. Assessment of risk factors for GHPs with neoplastic transformation in univariate logistic regression. 
GHPs patients who had history of anaemia showed higher risk of neoplastic transformation than GHPs patients 
who did not have history of anaemia (OR = 3.729, 95%CI: 1.099–12.649, P = 0.035). OR, odds ratio; CI, 
confidence interval.
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and 39 of these patients were agreed to participate in this study. We finally succeeded in reviewing 16 GHP 
patients who had neoplastic transformation and 39 GHP patients who had no evidence of neoplastic transfor-
mation (subsequently referred to as pure GHPs). We analyzed the difference in the participation rate between 
the two groups (53% vs 65%), but this showed no significance, with P value of 0.285. We excluded patients who 
had polyposis syndromes such as Juvenile polyposis, Peutz-Jeghers syndrome, Cronkhite-Canada syndrome. 
Informed consent was obtained from all individual participants included in the study. The study was approved 
by Beijing Friendship Hospital Ethics Committee (Certificate number is 2017-P2-110-01) and registered in the 
Chinese Clinical Trial Registry, World Health Organization (Registered number is ChiCTR1800014493).
All 55 patients had blood taken to measure their fasting serum gastrin-17 concentration (normal range 
35–100 pg/ml, ELISA), serum anti-parietal cell antibody (PCA, abnormal >1:80, IIFA), serum anti-intrinsic factor 
antibody (IF, abnormal >1:20, ELISA), serum thyroid function tests (TFTs), hemoglobin (male 120–160 g/l, female 
110–150 g/l), serum vitamin B12 (abnormal <190 pg/ml), serum iron (normal range 7.8–32.2 umol/l), serum fer-
ritin (normal range 11.0–306.0 ng/ml) and H. pylori serology. These hematological and biochemical tests were 
undertaken using standard laboratory procedures. H. pylori status was determined by serum H. pylori IgG and 
13C-urea breath test (UBT) or by histological evaluation of gastric biopsies. All 55 patients had a serum H. pylori 
IgG test. 44 additionally underwent UBT and 4 patients had histological evaluation. As long as one test result was 
positive, the final result was deemed positive. In patients in whom both the serum IgG test and UBT were nega-
tive, the final result was deemed negative. H. pylori negative patients did not have any prior eradication therapy or 
receive any proton pump inhibitor / H2 receptor antagonist before the test. Hypergastrinemia was diagnosed when 
the fasting serum gastrin concentration was at least two times higher than the upper limit of the normal range.
All the GHPs were treated by endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) 
or surgery. White light imaging (WLI) gastroscopy was performed using Olympus GIF H260 endoscopes. EMR 
or ESD was performed using GIF Q260J endoscopes. Using WLI, GHPs normally demonstrate a strong reddish 
coloration; they are usually semispherical when small or semi-pedunculated to pedunculated when they become 
larger. We describe the appearance as “strawberry-like” polyps. When GHPs harbor dysplasia or adenocarcinoma, 
this always appeared to be associated with surface erosion, especially with dirty or purulent ulcers being seen on 
the surface of the polyps (Fig. 1).
Histological slides were re-evaluated by an experienced pathologist according to the WHO Classification 
of Tumours of the Digestive System. We used the updated Sydney System to diagnose atrophic gastritis and the 
OLGA (Operative Link on Gastritis Assessment) system to evaluate the risk of gastric cancer34–36. The back-
ground biopsies were taken from the antrum and corpus/fundus, with two endoscopic bites being taken at each 
site. Elevated fasting serum gastrin concentrations and the presence of anti-parietal cell antibody or anti-intrinsic 
factor antibodies were also used to corroborate the diagnosis of AMAG24. The detailed demographic features and 
OLGA stages of the GHPs with neoplastic transformation were showed in Supplementary Table S1.
Statistical analysis was performed using SPSS 22. Quantitative variables were described and analyzed using 
the mean ± SD and student t test, whereas categorical variables were described using frequency and proportions. 
The Chi-square test was used to test for differences between groups. Fisher’s exact test was used for statistical 
comparisons as appropriate. Univariate and multivariate logistic regression analysis was performed to explore the 
association of risk factors. P values < 0.05 were considered statistically significant. All p values were two-sided.
ethical statement. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Data availability
The datasets generated and analyzed during the current study are available from the corresponding author on 
reasonable request.
Figure 1. WLI shows multiple GHPs with neoplasia in the corpus, ‘strawberry-like’ with erosions on the 
surface. This original image was processed in photoshop for changing to 300 bpi.
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